CTOs on the Move

OtisMed Corporation

www.otismed.com

 
OtisMed Corporation is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.otismed.com
  • 1600 Harbor Bay Pkwy
    Alameda, CA USA 94502
  • Phone: 888.684.7633

Executives

Name Title Contact Details

Similar Companies

Ardian

Ardian is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triage Wireless

Provides private mortgage insurance to residential mortgage lenders, including mortgage bankers, mortgage brokers, commercial banks, and savings institutions. (Nasdaq:TGIC).

Almost Family

Almost Family is a leading provider of home health nursing, rehabilitation and personal care services. We are a family of companies with names you can trust. For over thirty years, we have been providing skilled compassionate home health care in our local communities. We bring our expertise into the home - the ideal setting to promote healing, comfort and support to those facing the challenges of aging. Our Senior Advocacy philosophy addresses these challenges in a revolutionary new way. Our clinical team looks beyond the obvious needs of the patient to become advocates in all dimensions of physical, mental and emotional well-being. Our goal is to promote independence, allowing seniors to age in place for as long as possible.

Henry Ford Health System

The Henry Ford Health System is a comprehensive, integrated, non-profit health care organization in Metro Detroit.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.